VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma

Inclusion Criteria:

* Male or female subject 18 years or older
* Diagnosis of B-cell lymphoma (CD20+) of

  * follicular lymphoma (grades 1, 2, and 3) or
  * marginal zone lymphoma (extranodal, nodal, and splenic)
* Documented relapse or progression following prior anti-neoplastic treatment.
* At least 1 measurable lymph node mass that is \>1.5 cm.
* No active CNS lymphoma
* Voluntary consent

Exclusion Criteria:

* Previous treatment with VELCADE
* Any anti-neoplastic or experimental therapy within 3 weeks before the first dose of study drug.
* Any treatment with nitrosoureas within 6 weeks before the first dose of study drug.
* Treatment with Zevalin™ or Bexxar® within 10 weeks before the first dose of study drug.
* Rituximab, Campath® or other unconjugated therapeutic antibody within 4 weeks before the first dose of study drug.
* Radiation therapy within 3 weeks before the first dose of study drug.
* Major surgery within 2 weeks before the first dose of study drug.
* Peripheral neuropathy or neuropathic pain
* History of allergic reaction attributable to compounds containing boron or mannitol
* Known anaphylaxis or hypersensitivity to any component of rituximab
* Diagnosed or treated for a selected malignancies other than NHL within 5 years.
* Active systemic infection requiring treatment
* Female subjects must not be pregnant, breast-feeding, or become pregnant during the course of the study.
* Male subjects who do not agree to use an acceptable method of contraception for the duration of the study
* Any serious medical or psychiatric illness likely to interfere with participation in this clinical study
* Concurrent treatment with another investigational agent. Concurrent participation in non-treatment studies is allowed, if it will not interfere with participation in this study.